Skip to search formSkip to main contentSkip to account menu
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.
View on PubMed
Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.
TLDR
The type of bisphosphonate may play a role and previous dental procedures may be a precipitating factor for this complication and length of exposure seems to be the most important risk factor.
View on PubMed
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.
TLDR
The R-ISS is a simple and powerful prognostic staging system, and it is recommended for use in future clinical studies to stratify patients with NDMM effectively with respect to the relative risk to their survival.
View on PubMed
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.
View on PubMed
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
TLDR
Lenalidomide plus dexamethasone is more effective than high-dose dexamETHasone alone in relapsed or refractory multiple myeloma.
View on PubMed
Hematological findings and complications of COVID‐19
TLDR
COVID‐19 infected patients, whether hospitalized or ambulatory, are at high risk for venous thromboembolism, and an early and prolonged pharmacological thromboprophylaxis with low molecular weight heparin is highly recommended.
View on Wiley
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
TLDR
Bortezomib plus melphalan-prednisone alone in patients with newly diagnosed myeloma who were ineligible for high-dose therapy was superior to melphAlan-predisonsone alone.
View on PubMed
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
TLDR
In patients with relapsed multiple myeloma, the addition of carfilzomib to lenalidomide and dexamethasone resulted in significantly improved progression-free survival at the interim analysis and had a favorable risk-benefit profile.
View on PubMed
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
TLDR
The addition of daratumumab to lenalidomide and dexamethasone significantly lengthened progression-free survival among patients with relapsed or refractory multiple myeloma.
View on PubMed
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.
TLDR
Patients with relapsed or refractory multiple myeloma who received a combination of elotuzumab, lenalidomide, and dexamethasone had a significant relative reduction of 30% in the risk of disease progression or death.
View on PubMed
...
...
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License